In a report released today, Michael Matson from Needham reiterated a Buy rating on SurModics (SRDX), with a price target of $61.00. The company’s shares closed last Monday at $44.81, close to its 52-week high of $49.00.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 15.3% and a 68.6% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings.
Currently, the analyst consensus on SurModics is a Moderate Buy with an average price target of $62.00.
See today’s analyst top recommended stocks >>
SurModics’ market cap is currently $627.5M and has a P/E ratio of 573.30. The company has a Price to Book ratio of 6.93.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
SurModics, Inc. engages in the provision of medical device and in vitro diagnostic technologies to the healthcare industry. It operates through the Medical Device and In Vitro Diagnostics segments. The Medical Device segment designs, develops, and manufactures interventional medical devices, surface modification coating technologies, as well as drug-delivery coating technologies. The In Vitro Diagnostics segment consists of component products and technologies for diagnostic test kits and biomedical research applications. The company was founded in June 1979 and is headquartered in Eden Prairie, MN.
